Stock Events

Stock Events

CapForce 

$0.1
0
+$0.1+12,400% Today

Statistics

Day High
23
Day Low
23
52W High
31
52W Low
7.13
Volume
41
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q2 2025
Q3 2025
Q1 2026
Next
-1.4
-1.07
-0.73
-0.4
Expected EPS
N/A
Actual EPS
N/A

Financials

218.55%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
10.39MRevenue
22.71MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CFOR. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap11.61B
Guardant Health, Inc. specializes in liquid biopsies and cancer diagnostics, directly competing with Opgen's diagnostic solutions for detecting pathogens and antibiotic resistance genes.
Illumina
ILMN
Mkt Cap20.63B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, competing in the broader market of genomic analysis where Opgen also operates.
Qiagen NV
QGEN
Mkt Cap7.06B
Qiagen N.V. offers sample to insight solutions including infectious disease diagnostics, directly competing with Opgen's focus on molecular diagnostics.
Thermo Fisher Scientific
TMO
Mkt Cap174.37B
Thermo Fisher Scientific Inc. offers a wide range of diagnostics and research solutions, including those for infectious disease, competing with Opgen's diagnostic products.
Pacific Biosciences of California
PACB
Mkt Cap496.78M
Pacific Biosciences of California, Inc. provides sequencing systems that compete with Opgen's genomic analysis technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics, Inc. is involved in CRISPR technology for genetic editing, which could compete with Opgen's genomic approaches for diagnostics and treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals, potentially competing with Opgen's treatments and diagnostics in genetic diseases.
Adaptive Biotechnologies
ADPT
Mkt Cap2.28B
Adaptive Biotechnologies Corp. focuses on the immune-driven medicine space, including diagnostics that could compete with Opgen's offerings in infection and resistance detection.

About

CapForce Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. In addition, the company offers listing sponsorship and consultancy services. CapForce Inc. was formerly known as OpGen, Inc. and changed its name to CapForce Inc. in February 2026. CapForce Inc. was incorporated in 2001 and is based in Clarksburg, Maryland.
Show more...
CEO
ISIN
US68373L5057

Listings

MU
DE
650.MU
LSE
GB
0A8L.LSE
OTCM
US
OPGN
OTC Link
US
CFOR

0 Comments

Share your thoughts

FAQ

What is CapForce stock price today?▼
The current price of CFOR is $0.1 USD — it has increased by +12,400% in the past 24 hours. Watch CapForce stock price performance more closely on the chart.
What is CapForce stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CapForce stocks are traded under the ticker CFOR.
When is the next CapForce earnings date?▼
CapForce is going to release the next earnings report on May 19, 2026.
What is CapForce revenue for the last year?▼
CapForce revenue for the last year amounts to 10.39M USD.
What is CapForce net income for the last year?▼
CFOR net income for the last year is 22.71M USD.
In which sector is CapForce located?▼
CapForce operates in the Other sector.
When did CapForce complete a stock split?▼
CapForce has not had any recent stock splits.